Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 1).

Chiang, Chern-En, Chao, Tze-Fan, Choi, Eue-Keun, Lim, Toon Wei, Krittayaphong, Rungroj, Li, Mingfang, Chen, Minglong, Guo, Yutao ORCID: 0000-0002-7626-7751, Okumura, Ken and Lip, Gregory YH ORCID: 0000-0002-7566-1626 (2022) Stroke Prevention in Atrial Fibrillation: A Scientific Statement of JACC: Asia (Part 1). JACC. Asia, 2 (4). pp. 395-411.

Access the full-text of this item by clicking on the Open Access link.

PDF
Stroke Prevention in Atrial Fibrillation A Scientific Statement of iJACC Asiai (Part 1).pdf - Open Access published version
Download (1MB) | Preview

Official URL: http://dx.doi.org/10.1016/j.jacasi.2022.05.005

Abstract

Atrial fibrillation is the most common sustained cardiac arrhythmia and is associated with substantial increases in the risk of stroke and systemic thromboembolism. With the successful introduction of the first non-vitamin K antagonist direct oral anticoagulant (NOAC) in 2009, the role of vitamin K antagonists has been replaced in most clinical settings except in a few conditions when NOACs are contraindicated. Data for the use of NOACs in different clinical scenarios have been accumulating in the recent decade, and a more sophisticated strategy for atrial fibrillation patients is now warranted. JACC: Asia recently appointed a working group to summarize the most updated information regarding stroke prevention in AF. This statement aimed to provide possible treatment option in daily practice. Local availability, cost, and patient comorbidities should also be considered. Final decisions may still need to be individualized and based on clinicians' discretion. This is the part 1 of the whole statement.

Item Type:	Article
Uncontrolled Keywords:	ABC, atrial fibrillation better care, AF, atrial fibrillation, Asia, NOAC, non-vitamin K antagonist oral anticoagulant, OAC, oral anticoagulant, PCI, percutaneous coronary intervention, TAVI, transcatheter aortic valve implantation, VKA, vitamin K antagonist, atrial fibrillation, non–vitamin K antagonist oral anticoagulant, stroke, vitamin K antagonist
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences
Depositing User:	Symplectic Admin
Date Deposited:	12 Oct 2023 14:30
Last Modified:	12 Oct 2023 14:31
DOI:	10.1016/j.jacasi.2022.05.005
Open Access URL:	https://doi.org/10.1016/j.jacasi.2022.05.005
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3173640